Aramco Unveils Recycled Basketball Courts, Boosting "Shoot for the Future" Project
29.11.2024 02:45:00 CET | Business Wire | Press release
Aramco, one of the world’s leading integrated energy and chemicals companies, has unveiled the first three renovated community basketball courts on Tuesday in Dongdan basketball community, Beijing, China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241128606707/en/
Aramco has unveiled the first three renovated community basketball courts on Tuesday in Beijing, China. (Photo: Business Wire)
These courts, which were built with innovative and advanced materials, with the flooring made partly from recycled plastic, are part of Aramco’s “Shoot for the Future” basketball court revamp project, with the goal of injecting new energy into community basketball in China.
The project also aims to showcase the increasingly important role that advanced materials can play in a circular carbon economy, while helping with Aramco’s objective to support and empower communities and youth through sports, and to bring green development and recycling technology to a new height as well.
Nader Al-Arfaj, Managing Director in China of Aramco Asia, said that these courts not only tell an inspiring story about how Aramco aims to empower communities and individuals through sports, but also showcase Aramco's leadership in innovation, highlighting how we can use advanced materials to shape a better future.
“I think the significance of our cooperation is quite profound,” Jian Jiang, General Manager of CBA Company, the Chinese Basketball League operation unit, said. “The project carries many meanings behind it, such as its high-tech content, innovation, social responsibility, circular economy, and many other modern concepts. In fact, this project has inspired fans a lot.”
Xiaochuan Zhai, a top Chinese basketball player, said the floor has more mesh like holes, “So, water drains away quickly after rain, which makes it better than the previous kind of floors.”
Hansen Yang, a talented young Chinese player said, “The court's color is very bright, and its rebound and anti-slip effects are quite good, so it's more comfortable to play on it.”
To bring this project to life, Aramco has worked closely with its chemical arm SABIC, and Enlio, the exclusive supplier for 3X3 basketball floors for the Tokyo and Paris Olympics. “Central to these courts is a professional-standard flooring which uses recycled materials,” Al-Arfaj added.
Aramco stressed it will continue working with partners to achieve the ambition of building courts across the country.
Al-Arfaj said, “I think we will all find these courts exceptionally impressive, and we look forward to seeing the community enjoy these courts for years to come.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128606707/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom